Cicardi, M; Banerji, A; Bracho, F et al.
Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary AngioedemaNEW ENGLAND JOURNAL OF MEDICINE. Bd. 363. H. 6. 2010 S. 532-541
Bork, K
Icatibant, a Selective Bradykinin B2 Receptor Antagonist Used in Hereditary Angioedema Due to C1 Inhibitor DeficiencyJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. Bd. 125. H. 2. 2010 S. AB165-AB165
Brosch, S; Haak, S; Lorenz, B et al.
IL-22 contributes to disease progression in Leishmania major-infected miceJOURNAL OF INVESTIGATIVE DERMATOLOGY. Bd. 130. 2010 S. S126-S126
Dinges, S; Kostka, SL; Becker, C et al.
IL-23 is not required for Th17 induction in murine cutaneous leishmaniasisEXPERIMENTAL DERMATOLOGY. Bd. 19. H. 2. 2010 S. 199-199
Kostka, SL; Dudeck, A; Kautz-Neu, K et al.
Impaired Th1 and Th17 priming in mast cell-deficient KitW-sh/KitW-shmiceEXPERIMENTAL DERMATOLOGY. Bd. 19. H. 2. 2010 S. 199-199
Correll, Anita; Tüttenberg, Andrea; Becker, Christian et al.
Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccinationExperimental dermatology. Bd. 19. H. 8. Oxford: Wiley-Blackwell 2010 S. e213 - e221
Mitzel-Kaoukhov, H; Staubach, P; Muller-Brenne, T
INTRAVENOUS IMMUNOGLOBULIN AS A THIRD-LINE THERAPY IN CHRONIC SPONTANEOUS URTICARIAANNALS OF ALLERGY ASTHMA & IMMUNOLOGY. Bd. 105. H. 3. 2010 S. 245-246
Maurer, M; von Stebut, E
Investigative dermatology: where do we stand and where do we go?EXPERIMENTAL DERMATOLOGY. Bd. 19. H. 10. 2010 S. 857-857
Ehrchen, JM; Roebrock, K; Foell, D et al.
Keratinocytes Determine Th1 Immunity during Early Experimental LeishmaniasisPLOS PATHOGENS. Bd. 6. H. 4. 2010 S. -
Ehrchen, JM; Roebrock, K; Nippe, N et al.
Keratinocytes determine Th1/Th2 dichotomy during early experimental leishmaniasisEXPERIMENTAL DERMATOLOGY. Bd. 19. H. 2. 2010 S. 185-185